UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000034373 |
|---|---|
| Receipt number | R000039186 |
| Scientific Title | A phase II, multicenter study to investigate the safety and efficacy of atezolizumab monotherapy as a sequential therapy following chemoradiotherapy in patients with locally advanced unresectable esophageal cancer |
| Date of disclosure of the study information | 2018/11/01 |
| Last modified on | 2023/06/16 07:11:44 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2018/10/04 10:41:43 | ||
| 2 | Update | 2018/10/05 10:40:50 | UMIN ID1 |
|
| 3 | Update | 2019/01/07 09:31:15 | Recruitment status |
|
| 4 | Update | 2020/03/18 13:37:00 | Key inclusion criteria Key inclusion criteria |
|
| 5 | Update | 2020/03/18 13:44:36 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel Institutions |
|
| 6 | Update | 2020/03/18 13:47:07 | Date of IRB Last follow-up date |
|
| 7 | Update | 2020/04/05 19:21:08 | Organization |
|
| 8 | Update | 2021/04/05 09:48:17 | Recruitment status Last follow-up date |
|
| 9 | Update | 2021/04/05 09:48:40 | Last follow-up date |
|
| 10 | Update | 2023/06/16 07:00:45 | Recruitment status Date trial data considered complete |
|
| 11 | Update | 2023/06/16 07:11:44 | Last follow-up date Date of closure to data entry |
